ANNOUNCEMENT: The First Annual Meeting on the Experimental Therapeutics for
Human Cancer, June 11-13, 1998, Frederick, MD
The First Annual Meeting on the Experimental Therapeutics for
Human Cancer is to be held at Hood College in Frederick, Maryland,
from Thursday evening, June 11 through Saturday, June 13, 1998.
The purpose of the conference is to bring together the top basic
and clinical scientists to the same forum and to allow for interaction
and discussion on how best to develop new rationally designed therapies
George Vande Woude
Thus far, an exciting program is planned which includes
the following speakers:
John Mendelsohn, MD Anderson
Richard Klausner, NCI.
New Molecular Targets: Signalling/Kinases:
Sara Courtneidge, Sugen, Inc.
George Vande Woude, Frederick
New Molecular Targets: RAS, p53, cell cycle, apoptosis:
Chi Dang, Hopkins
Albert Baldwin, UNC
Steve Friend, U. Washington;
Ed Sausville, NCI
New Molecular Targets: Cell Adhesion Molecules:
Erkki Ruoslahti, Burnham Institute;
William Stetler-Stevenson, NCI
Molecular Profiling and Cancer Response:
Edison Liu, NCI
William Hait, Cancer Inst. NJ
Drug Development/Phase I and II Trials/Regulatory Issues:
Michael Friedman, FDA
Ross Donehower, Hopkins
Robert C. Jackson, Chiroscience
Reagent-Based Immunologic Therapies
Ira Pastan, NCI
Mark Kaminski, U. Michigan
DNA/RNA-Based Therapies, Gene Therapy
Allan Balmain, Onyx
Brian Huber, Glaxo-Wellcome
Plus additional topics to be included as well.
Registration fees are $650 which includes room and board for the confenence.
Registration and abstract submission via the internet is encouraged. Visit
our website at http://www.facsi.org. The deadline for abstract submission
has been extended to May 1, 1998.
Additional registration or travel information can be obtained by contacting
Margaret Fanning, FACS, P.O. Box 249, 12120 Main Street,
Libertytown, MD 21762, Phone: 301 898-9266, Fax: 301-898-9173,
e-mail: margaret at facsi.org or by visiting our
Please mark this down on your calendars!